Abstract
Purpose/Objective: Amifostine reduces xerostomia in patients receiving head and neck radiotherapy (RT) but is associated with significant toxicity and cost. In this retrospective review we compared records of patients irradiated with and without amifostine for grades of acute xerostomia, mucositis, drug-related toxicity, as well as drug cost and disease outcomes.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
